These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18280694)

  • 1. A short series of antidiabetic sulfonylureas exhibit multiple ligand PPARgamma-binding patterns.
    Arrault A; Rocchi S; Picard F; Maurois P; Pirotte B; Vamecq J
    Biomed Pharmacother; 2009 Jan; 63(1):56-62. PubMed ID: 18280694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators.
    Kumar R; Mittal A; Ramachandran U
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4613-8. PubMed ID: 17574414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
    Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
    Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect.
    Kharbanda C; Alam MS; Hamid H; Javed K; Dhulap A; Bano S; Ali Y
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4601-5. PubMed ID: 26384286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
    Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
    Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
    Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
    J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach.
    Scarsi M; Podvinec M; Roth A; Hug H; Kersten S; Albrecht H; Schwede T; Meyer UA; Rücker C
    Mol Pharmacol; 2007 Feb; 71(2):398-406. PubMed ID: 17082235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, development and evaluation of novel dual PPARδ/PPARγ agonists.
    Gathiaka S; Nanayakkara G; Boncher T; Acevedo O; Wyble J; Patel S; Patel A; Shane ME; Bonkowski B; Wieczorek J; Rong Y; Huggins K; Smith F; Amin RH
    Bioorg Med Chem Lett; 2013 Feb; 23(3):873-9. PubMed ID: 23273519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New oral antidiabetic drugs. Synthesis and structure-activity relationships.
    Francia E; Marin A; Verdejo F; Sanchez MS; Morell J
    Boll Chim Farm; 1975 Jul; 114(7):379-92. PubMed ID: 1164447
    [No Abstract]   [Full Text] [Related]  

  • 12. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
    Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
    ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).
    Dong X; Zhang Z; Wen R; Shen J; Shen X; Jiang H
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5913-6. PubMed ID: 17010604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
    Winczyk K; Kunert-Radek J; Gruszka A; Radek M; Ławnicka H; Pawlikowski M
    Neuro Endocrinol Lett; 2009 Mar; 30(1):107-10. PubMed ID: 19300395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPARγ and SUR agonists.
    El-Zahabi MA; Elbendary ER; Bamanie FH; Radwan MF; Ghareib SA; Eissa IH
    Bioorg Chem; 2019 Oct; 91():103115. PubMed ID: 31310882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of docking-based 3D-QSAR models for PPARgamma full agonists.
    Guasch L; Sala E; Valls C; Mulero M; Pujadas G; Garcia-Vallvé S
    J Mol Graph Model; 2012 Jun; 36():1-9. PubMed ID: 22503857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Synthesis of phenyloxyisobutyric acid derivatives and their antidiabetic activity in vitro].
    Zeng QL; Wang HQ; Luo H; Gao XP; Liu ZR; Li BG; Wang FP; Zhao YF
    Yao Xue Xue Bao; 2006 Feb; 41(2):108-14. PubMed ID: 16671538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies.
    Sundriyal S; Viswanad B; Bharathy E; Ramarao P; Chakraborti AK; Bharatam PV
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3192-5. PubMed ID: 18482837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.